Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG114

—

efca146e-788e-5160-ab9f-56865a1e523b

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • TNFA_SIGNALING_VIA_NFKB+0.492
  • HEDGEHOG_SIGNALING+0.381
  • TGF_BETA_SIGNALING+0.342
  • COAGULATION+0.284
  • INFLAMMATORY_RESPONSE+0.271
  • ANGIOGENESIS+0.264
  • ESTROGEN_RESPONSE_LATE+0.260
  • ESTROGEN_RESPONSE_EARLY+0.255
  • IL2_STAT5_SIGNALING+0.242
  • ANDROGEN_RESPONSE+0.236

Top 10 suppressed

  • E2F_TARGETS-0.486
  • G2M_CHECKPOINT-0.331
  • MYC_TARGETS_V2-0.277
  • DNA_REPAIR-0.271
  • MYC_TARGETS_V1-0.253
  • INTERFERON_ALPHA_RESPONSE-0.215
  • INTERFERON_GAMMA_RESPONSE-0.214
  • WNT_BETA_CATENIN_SIGNALING-0.170
  • ALLOGRAFT_REJECTION-0.142
  • NOTCH_SIGNALING-0.136

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG329
mng-umap@100
——0.889
2SRR8613755
breast-umap@18
—F0.845
3SRR8613813
breast-umap@18
—D0.821
4TCGA-CV-7411-01A-11R-2081-07
head-neck@1
——0.797
5C3N-00738
lung-landscapes@6
—cohortMD20.797
6TCGA-FD-A6TI-01A-11R-A32O-07
bladder-landscape@3
——0.795
7TCGA-BH-A0HI-01A-11R-A084-07
breast-umap@18
—B0.794
8TCGA-22-4605-01A-21R-2125-07
lung-landscapes@6
—cohortSQ10.794
920060059.TNBC
breast-umap@18
—F0.788
10MNG1171
mng-umap@100
——0.786

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 34 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
TNFA_SIGNALING_VIA_NFKB0.492Inavolisib— uncovered
HEDGEHOG_SIGNALING0.381Inavolisib— uncovered
TGF_BETA_SIGNALING0.342Inavolisib— uncovered
COAGULATION0.284Binimetinib— uncovered
INFLAMMATORY_RESPONSE0.271Idelalisib— uncovered
ANGIOGENESIS0.264Remibrutinib— uncovered
ESTROGEN_RESPONSE_LATE0.260Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.255Inavolisib— uncovered
IL2_STAT5_SIGNALING0.242Idelalisib— uncovered
ANDROGEN_RESPONSE0.236Inavolisib— uncovered
PEROXISOME0.230Idelalisib— uncovered
BILE_ACID_METABOLISM0.228Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.220Inavolisib— uncovered
ADIPOGENESIS0.215Inavolisib— uncovered
PROTEIN_SECRETION0.207Remibrutinib— uncovered
UV_RESPONSE_UP0.207Idelalisib— uncovered
HEME_METABOLISM0.205Temsirolimus— uncovered
IL6_JAK_STAT3_SIGNALING0.199Inavolisib— uncovered
COMPLEMENT0.191Inavolisib— uncovered
HYPOXIA0.173Idelalisib— uncovered